Sweden's SynAct Pharma Q2 net loss narrows on lower expenses

SynAct Pharma AB

20/08/2026 06:39

Overview
Sweden biotech firm's Q2 net loss and loss per share narrowed on lower operating expenses
Company reported no revenue for the quarter
Positive Phase 2b study results for resomelagon support Phase 3 design and partnering talks

Outlook
Company did not provide specific financial or operational guidance for future periods in the press release

Result Drivers
OPERATING EXPENSES - Q2 net loss narrowed due to lower operating expenses
CLINICAL PROGRESS - Completion of dosing in Phase 2b ADVANCE study and positive effects for resomelagon in rheumatoid arthritis supported regulatory and partnering discussions

Company press release: ID:nMFN7VS91F

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
 
SEK 0
 
Q2 Adjusted Loss Per Share
 
SEK 0.39
 
Q2 Net Loss
 
SEK 22.03 mln
 
Q2 Cash Flow From Operating Activities
 
-SEK 34.54 mln
 
Q2 Operating Expenses
 
SEK 24.56 mln
 

Analyst Coverage
Wall Street's median 12-month price target for SynAct Pharma AB is SEK30.00, about 39.9% above its August 19 closing price of SEK21.45

Reuters Recommended Reads
Aug 19 - Sweden's Cantargia narrows H1 loss, raises SEK 132 mln
Aug 19 - Denmark's Lundbeck Q2 revenue rises 7% driven by Vyepti and Rexulti
Aug 17 - EyePoint's drug for age-related eye disease fails late-stage trial, shares tank

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)